EZH2 and Miyoshi myopathy: The above findings confirm that the TIGIT-blocking monoclonal antibody can significantly enhance the function and anti-tumor effect of NK in the MM tumor microenvironment compared to EZH2 inhibition alone or TIGIT blockade in the presence of EZH2 inhibition.